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study.  Results: Total cerebrovascular events were signifi-
cantly higher in participants with baseline CKD (0.66%/year) 
compared with participants free of CKD (0.28%/year). A sig-
nificantly higher rate of events was observed in CKD partici-
pants. Intensive antihypertensive therapy in participants 
without CKD at baseline resulted in a 55% significant reduc-
tion of any stroke (hazard ratio 0.447; 95% CI 0.227–0.880) 
and a 50% reduction of non-fatal stroke (hazard ratio 0.498; 
95% CI 0.250–0.993). In participants with CKD at baseline, the 
occurrence of any stroke was reduced by 38% (hazard ratio 
0.623; 95% CI 0.361–1.074) and non-fatal stroke by 36% (haz-
ard ratio 0.642; 95% CI 0.361–1.142). Test for interaction was 
NS between the 2 groups. Changes in other CVD outcomes 
did not reach statistical significance.  Conclusions: These 
findings suggest that intensive antihypertensive therapy of-
fers significant cerebrovascular protection in diabetic par-
ticipants without CKD at baseline, but significant benefit 
to patients with CKD cannot be excluded. 
 © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: Persons with chronic kidney disease (CKD) rep-
resent a population prone to cardiovascular disease (CVD) 
but vulnerable to adverse medication effects. We assessed 
the impact of intensive antihypertensive therapy on the 
cerebrovascular and other CVD outcomes in high-risk pa-
tients with type 2 diabetes and baseline CKD.  Methods: Us-
ing current guideline criteria, 1,726 (36.9%) of 4,678 partici-
pants in the Action to Control Cardiovascular Risk in Diabe-
tes (ACCORD) blood pressure (BP) arm had mild to moderate 
CKD (CKD1–3B) at baseline. Participants of this study were 
randomized to intensive (systolic <120 mm Hg) or standard 
(systolic <140 mm Hg) BP goals. Fatal and non-fatal stroke 
were pre-specified secondary outcomes of the ACCORD 
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 Introduction 
 Chronic kidney disease (CKD) affects approximately 
11% of the US adult population and it is a marker of in-
creased cardiovascular risk regardless of cause. The prev-
alence of earlier stages of CKD is more than 100 times 
greater than the prevalence of end-stage renal disease 
(ESRD)  [1]. Recent data indicate that CKD may carry a 
cardiovascular disease (CVD) risk equivalent to diabetes 
and/or pre-existing CVD  [2] . Prevention of CKD or re-
tardation of disease progression has been advocated as 
another strategy toward cardiovascular protection  [3] . 
Observational studies suggest a strong association be-
tween elevated blood pressure (BP), CVD and risk of re-
nal function decline or ESRD, whereas individuals with 
BP below conventional thresholds show better preserva-
tion of renal function  [4–6] .
 In the Systolic Blood Pressure Intervention Trial 
(SPRINT), CVD events and mortality were reduced and 
the results were similar across all major subgroups, in-
cluding the 28% with CKD  [7] . However, SPRINT ex-
cluded participants with known diabetes mellitus (DM). 
Therefore, the optimal BP goal for diabetic participants 
with CKD and more importantly with mild to moderate 
CKD has not been determined in prospective random-
ized trials. In the Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) trial, participants with type II 
DM and hypertension had a significantly lower incidence 
of stroke with intensive BP therapy, but no significant re-
duction in other cardiovascular outcomes  [8] . ACCORD 
enrolled participants with mild to moderate CKD (CKD 
I–III).
 We therefore investigated the impact of CKD and in-
tensive antihypertensive therapy on health outcomes, in-
cluding cerebrovascular events in this high-risk popula-
tion with type 2 diabetes.
 Methods 
 ACCORD was a large (10,251 participants), multi-center, pro-
spective, randomized study that aimed to evaluate the effects of 
intensive glycemic, lipid, and BP control vs. standard therapy in 
high-risk participants with type 2 DM. The study design included 
3 intervention arms (glycemia, lipid, and BP) with all participants 
participating in the glycemia intervention  [9] . Study participants 
were further randomized to the lipid and the BP studies in a double 
2 × 2 factorial design  [8, 10] . The study design and the inclusion/
exclusion criteria have been reported in detail previously  [8–10] . 
The BP trial included 4,733 participants with DM and treated or 
untreated systolic BP 130–180 mm Hg, and serum creatinine  ≤ 1.5 
mg/dl, who were randomly assigned to standard antihypertensive 
therapy (target systolic BP <140 mm Hg) or intensive antihyper-
tensive therapy (target systolic BP <120 mm Hg).
 The study was performed in accordance with the Helsinki Dec-
laration, and protocol approval was granted by the IRB or Ethics 
Committees of all participating center, and by a review panel at the 
NHLBI. All participants were informed in detail and then they 
consented to participate in the study.
 Estimated glomerular filtration rate (eGFR) was calculated by 
using the Modification of Diet in Renal Disease (MDRD) formula. 
A 5-stage classification system was used to define CKD categories 
according to KDIGO recommendations  [11] . Stage I CKD was de-
fined as normal eGFR ( ≥ 90 ml/min/1.73 m 2 ) and increased albu-
min excretion (urine albumin/creatinine ratio  ≥ 30 μg/mg). Stage II 
CKD was defined as eGFR between 60 and 89 ml/min/1.73 m 2 and 
urine albumin/creatinine ratio  ≥ 30 μg/mg. Stage III was defined as 
eGFR between 30 and 59 ml/min/1.73 m 2 with or without albumin-
uria. Stage III CKD was further subdivided into CKD IIIA (eGFR 
30–44) and CKD IIIB (eGFR 45–59). Study participants with stag-
es I and II CKD were considered participants with mild CKD, while 
participants with stage III CKD were considered participants with 
moderate CKD. Most CKD III were CKD IIIB patients participants 
with stage IV and V CKD were not included in the ACCORD trial.
 A composite end-point including both non-fatal and fatal CVD 
events (first occurrence of non-fatal myocardial infarction (MI), 
non-fatal stroke, and cardiovascular death) was used as the pri-
mary end point of the study. Pre-specified secondary outcomes 
included cardiovascular and total mortality, fatal and non-fatal 
stroke, non-fatal MI, non-fatal and fatal congestive heart failure, 
major coronary events, and revascularization  [9] .
 Statistical Analysis 
 For  tables 1 and  2 , continuous variables are expressed as mean ± 
SD. When the distribution was highly skewed, the median was 
used and interquartile range is reported. Categorical variables are 
reported as numbers and percentages. Baseline characteristics be-
tween CKD and non-CKD participants as well as intensive vs. 
standard therapy in each group were compared using chi square, 
2-sample t tests, or Fisher’s exact tests.
 Cox proportional hazard models were used for the analyses of 
the primary and secondary outcomes in the intensive vs. standard 
BP control groups and according to whether CKD was present or 
not. Occurrences of these outcomes were compared with the use 
of hazard ratios and 95% CIs. Two-sided p values were obtained 
from likelihood ratio tests from Cox proportional-hazards regres-
sion analyses. Event rates are expressed as the percentage of events 
per 100 follow-up years, taking into account censoring of follow-
up data.
 Cox models contained a term representing study group assign-
ments plus terms accounting for the following prespecified strati-
fication variables: assignment to the lipid trial, assignment to the 
intensive glycemic intervention, assignment to receive fibrate in 
the lipid trial, the 7 clinical-center networks, the presence or ab-
sence of a previous cardiovascular event, and the following base-
line covariates: cardiovascular history, clinical center network, age 
(years), female (yes/no), BMI (kg/m 2 ), HbA1c (%), systolic BP, 
smoking status (yes/no), insulin use (yes/no), and antihyperten-
sive use (yes/no).
 Subgroup analyses for the consistency of the effects among sub-
groups of study participants were performed using interaction 
tests between subgroups and therapy effects.
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Table 1.  Baseline characteristics of entire BP cohort and by baseline CKD status
Overall (n = 4,678)  Baseline CKD status p value
 no CKD 
(n = 2,952)
with CKD 
(n = 1,726)
Age, years 62.2±6.9 61.6±6.5 63.2±7.3 <0.0001
Female sex 2,231 (47.7) 1,455 (49.3) 776 (45.0) 0.0042
Race/ethnicity 0.5512
African American 1,110 (23.7) 695 (23.5) 415 (24.0)
White 2,757 (58.9) 1,752 (59.3) 1,005 (58.2)
Hispanic 320 (6.8) 191 (6.5) 129 (7.5)
Other 491 (10.5) 314 (10.6) 177 (10.3)
Weight, kg 92.0±18.5 91.8±18.4 92.4±18.7 0.2621
BMI, kg/m2 32.2±5.6 32.0±5.5 32.3±5.7 0.0739
Smoking status <0.0001
Never 2,093 (44.8) 1,369 (46.4) 724 (42.0)
Former 1,959 (41.9) 1,234 (41.8) 725 (42.1)
Current 621 (13.3) 347 (11.8) 274 (15.9)
Serum creatinine, mg/dl 0.9±0.2 0.8±0.2 1.0±0.3 <0.0001
CKD <0.0001
No CKD 2,952 (63.1) 2,952 (100) 0 (0.0)
Stage I 693 (14.8) 0 (0.0) 693 (40.2)
Stage II 632 (13.5) 0 (0.0) 632 (36.6)
Stage III 401 (8.6) 0 (0.0) 401 (23.2)
Serum glucose, mg/dl 174.6±57.6 171.3±52.6 180.1±65.0 <0.0001
HbA1c, % 8.3±1.1 8.3±1.0 8.5±1.1 <0.0001
Duration of DM, years 11.0±8.0 10.2±7.6 12.5±8.4 <0.0001
Systolic BP 139.2±15.8 137.2±15.0 142.5±16.7 <0.0001
Diastolic BP 75.9±10.4 76.2±10.1 75.5±10.9 0.0251
Heart rate 73.1±11.6 72.8±11.3 73.6±12.1 0.0175
History of CVD 1,577 (33.7) 897 (30.4) 680 (39.4) <0.0001
History of CHF 201 (4.3) 95 (3.3) 106 (6.2) <0.0001
Insulin 1,728 (36.9) 979 (33.2) 749 (43.4) <0.0001
Merformin 2,682 (57.3) 1,724 (58.4) 958 (55.5) 0.0532
Any sulfonylurea 2,220 (47.5) 1,435 (48.6) 785 (45.5) 0.0386
Any antihypertensive agent 4,088 (87.4) 2,507 (84.9) 1,581 (91.6) <0.0001
ACE-inhibitors 2,439 (52.1) 1,503 (50.9) 936 (54.2) 0.0285
ARBs 791 (16.9) 482 (16.3) 309 (17.9) 0.1656
Any thiazide diuretic 1,000 (21.4) 623 (21.1) 377 (21.8) 0.5524
Beta blockers 1,196 (25.6) 674 (22.8) 522 (30.2) <0.0001
CCBs
Dihydropyridine 517 (11.1) 274 (9.3) 243 (14.1) <0.0001
Non-dihydropyridine 347 (7.4) 178 (6.0) 169 (9.8) <0.0001
Aspirin 2,447 (52.3) 1,535 (52.0) 912 (52.8) 0.5787
Statin 3,035 (64.9) 1,909 (64.7) 1,126 (65.2) 0.6938
Fibrate 307 (6.6) 181 (6.1) 126 (7.3) 0.1193
Potassium 4.5±0.7 4.4±0.4 4.5±1.0 <0.0001
LDL 110.0±36.7 110.2±35.9 109.7±38.1 0.6214
HDL
Female 51.3±13.8 52.0±13.7 50.0±13.9 0.0016
Male 41.7±11.7 42.0±11.2 41.3±12.5 0.1697
Triglycerides 147.0 (98.0–226.0) 143.0 (95.0–212.0) 158.0 (103.0–249.0) <0.0001
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Table 2.  Baseline characteristics of study participants by baseline CKD status and treatment arm
No CKD intensive 
(n = 1,469)
No CKD standard 
(n = 1,483)
With CKD intensive 
(n = 867)
With CKD standard 
(n = 859)
p value
Age, years 61.6±6.4 61.7±6.6 63.1±7.3 63.2±7.3 <0.0001
Female sex 722 (49.1) 733 (49.4) 393 (45.3) 383 (44.6) 0.0402
Race/ethnicity 0.5095
African American 337 (22.9) 358 (24.1) 204 (23.5) 211 (24.6)
White 899 (61.2) 853 (57.5) 502 (57.9) 503 (58.6)
Hispanic 89 (6.1) 102 (6.9) 65 (7.5) 64 (7.5)
Other 144 (9.8) 170 (11.5) 96 (11.1) 81 (9.4)
Weight, kg 91.7±19.1 91.9±17.8 92.9±19.7 92.0±17.5 0.4242
BMI, kg/m2 32.0±5.5 32.1±5.4 32.5±5.9 32.2±5.5 0.1749
Smoking status 0.0031
Never 672 (45.8) 697 (47.0) 366 (42.4) 358 (41.7)
Former 618 (42.1) 616 (41.6) 365 (42.2) 360 (41.9)
Current 178 (12.1) 169 (11.4) 133 (15.4) 141 (16.4)
Serum creatinine, mg/dl 0.8±0.2 0.8±0.2 1.0±0.3 1.0±0.3 <0.0001
CKD <0.0001
No CKD 1,469 (100) 1,483 (100) 0 (0.0) 0 (0.0)
Stage I 0 (0.0) 0 (0.0) 353 (40.7) 340 (39.6)
Stage II 0 (0.0) 0 (0.0) 308 (35.5) 324 (37.7)
Stage III 0 (0.0) 0 (0.0) 206 (23.8) 195 (22.7)
Serum glucose, mg/dl 171.8±51.9 170.8±53.2 182.9±65.6 177.4±64.3 0.0002
HbA1c, % 8.3±1.0 8.2±1.0 8.5±1.2 8.4±1.1 <0.0001
Duration of DM, years 10.2±7.6 10.2±7.7 12.5±8.3 12.5±8.4 <0.0001
Systolic BP 137.1±15.3 137.4±14.6 142.2±17.0 142.8±16.4 <0.0001
Diastolic BP 76.0±10.3 76.4±9.9 75.7±11.0 75.3±10.8 0.0629
Heart rate 72.7±11.4 72.8±11.2 73.5±12.4 73.6±11.9 0.0304
History of CVD 455 (31.0) 442 (29.8) 341 (39.3) 339 (39.5) <0.0001
History of CHF 55 (3.8) 40 (2.7) 53 (6.2) 53 (6.3) <0.0001
Insulin 495 (33.7) 484 (32.6) 359 (41.4) 390 (45.4) <0.0001
Metformin 866 (59.0) 858 (57.9) 461 (53.2) 497 (57.9) 0.0466
Any sulfonylurea 729 (49.6) 706 (47.6) 411 (47.4) 374 (43.5) 0.0445
Any antihypertensive agent 1,265 (86.1) 1,242 (83.7) 793 (91.5) 788 (91.7) <0.0001
ACE-inhibitors 784 (53.4) 719 (48.5) 451 (52.0) 485 (56.5) 0.0016
ARBs 230 (15.7) 252 (17.0) 152 (17.5) 157 (18.3) 0.3870
Any thiazide diuretic 313 (21.3) 310 (20.9) 183 (21.1) 194 (22.6) 0.8050
Beta blockers 343 (23.3) 331 (22.3) 272 (31.4) 250 (29.1) <0.0001
CCBs
Dihydropyridine 135 (9.2) 139 (9.4) 130 (15.0) 113 (13.2) <0.0001
Non-dihydropyridine 94 (6.4) 84 (5.7) 89 (10.3) 80 (9.3) <0.0001
Aspirin 780 (53.1) 755 (50.9) 473 (54.6) 439 (51.1) 0.2860
Statin 938 (63.9) 971 (65.5) 558 (64.4) 568 (66.1) 0.6602
Fibrate 95 (6.5) 86 (5.8) 63 (7.3) 63 (7.3) 0.3969
Potassium 4.5±0.5 4.4±0.4 4.5±0.5 4.6±1.3 <0.0001
LDL 111.5±37.8 108.9±33.9 110.5±36.9 108.8±39.2 0.1538
HDL
Female 52.2±13.6 51.7±13.9 49.5±12.8 50.6±15.0 0.0052
Male 41.9±11.1 42.0±11.4 40.4±10.9 42.2±13.8 0.6296
Triglycerides 142.5 (94.5–211.0) 143.0 (95.0–212.0) 158.0 (104.0–255.0) 158.0 (102.0–240.0)
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 No adjustments were made for multiple testing. Nominal 
p  values are reported throughout as simple guides to possible 
 associations. All analyses were performed at a central coordinat-
ing center using SAS 9.3 software (SAS Institute, Cary, N.C., 
USA).
 Results 
 Baseline 
 Data recording renal function were available for 4,678 
of the 4,733 participants in the BP arm of the ACCORD 
study. More than 60% of them were free of CKD (2,952 
participants; 63.1%), while the remaining 1,726 partici-
pants (36.9%) had some degree of CKD. More specifi-
cally, 693 participants (14.8%) were classified as Stage I 
CKD, 632 participants (13.5%) as stage II CKD and 401 
(8.6%) as stage III CKD.
 The key baseline characteristics of study participants 
according to CKD status at baseline are described in  ta-
ble 1 . Participants with CKD were older by about 1.5 years 
on average, had higher waist circumference, were more 
frequently current smokers, had greater duration of dia-
betes and higher HbA1c levels, higher systolic BP values 
and higher rates for history of heart failure and CVD. For 
the treatment of diabetes, participants with CKD used in-
sulin and sulfonylureas more frequently and metformin 
less frequently than participants without CKD baseline. 
Antihypertensive agents were used more frequently by 
participants with CKD.
 Table 2 presents the main baseline characteristics ac-
cording to BP arm (intensive vs. standard) and CKD sta-
tus at baseline. Differences in baseline parameters be-
tween CKD and non-CKD participants are observed in 
each BP arm, similar to the total population. Importantly, 
however, no significant differences between the 2 BP 
arms (intensive vs. standard therapy) were observed, both 
for CKD and for non-CKD participants.
 Blood Pressure 
 At baseline, systolic BP was significantly higher in the 
CKD group as compared to the non-CKD group (142.5 ± 
16.7 vs. 137.2 ± 15.0 mm Hg, p < 0.0001;  table 1 ) but very 
similar between intensive and standard arms in both 
groups ( table 2 ). BP was significantly reduced in the in-
tensive arm in both CKD and non-CKD participants 
( fig. 1 ). At the end of the study, systolic BP in the standard 
arm was similar between CKD and non-CKD partici-
pants (134 mm Hg) and much lower in the intensive arm 
(122 mm Hg in CKD, 119 mm Hg in non-CKD partici-
pants). Of note, BP levels were consistently lower through-
out the study in non-CKD as compared to CKD partici-
pants both in the intensive and standard treatment arms 
( fig. 1 ).
 Fig. 1. Systolic BP according to BP arm and 
CKD status at baseline. 
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 Outcomes 
 Figure 2 presents the rates for the primary and second-
ary CVD outcomes according to CKD status at baseline. 
All outcomes occurred at a much higher annual rate in 
CKD participants as compared to non-CKD participants. 
The primary end point occurred at a rate of 2.99%/year in 
the CKD vs. 1.39%/year in the non-CKD participants (p < 
0.0001). Similar differences were noted in all secondary 
outcomes that include non-fatal MI, any and non-fatal 
stroke, CV and all-cause mortality, major coronary events 
and fatal and non-fatal heart failure ( fig. 2 ). Importantly, 
the risk of any stroke was more than 2.3 times higher in 
CKD as compared to non-CKD participants (hazard ratio 
2.3; 95% CI 1.5–3.5; p  < 0.0001) and that of non-fatal 
stroke was more than 2.2 times higher in CKD as com-
pared to non-CKD participants (hazard ratio 2.2; 95% CI 
1.4–3.4; p < 0.0001).
 The rates for the primary and secondary outcomes in 
participants without CKD according to assignment treat-
ment group are presented in  figure 3 a. In this group of 
participants, an intensive decrease in BP was associated 
with a significantly lower rate of any stroke (55% lower) 
and in non-fatal stroke (50% lower) when compared to 
the standard BP-lowering group (hazard ratio 0.447 and 
95% CI 0.227–0.880 for any stroke; hazard ratio 0.498 
and 95% CI 0.250–0.993 for non-fatal stroke, respective-
ly). A trend toward lower rates for the primary outcome, 
non-fatal MI and fatal or non-fatal heart failure was ob-
served with intensive therapy compared to standard 
therapy, but differences did not reach statistical signifi-
cance.
 In participants with CKD at baseline ( fig. 3 b), an in-
tense reduction in BP was associated with a trend toward 
reduced rates for the primary and all secondary outcomes, 
without reaching statistical significance. The reduction in 
outcomes was larger for any stroke (38%) and non-fatal 
stroke (36%), but statistical significance was not reached 
(hazard ratio 0.623 and 95% CI 0.361–1.074 for any 
stroke; hazard ratio 0.642 and 95% CI 0.361–1.142 for 
non-fatal stroke, respectively).
Primary outcome
Secondary outcomes
   Non-fatal MI
   Any stroke
   Non-fatal stroke
   Death any cause
   CVD death
   PO/Rev/non-fatal CHF
   Major coronary
   Any CHF
1.39% (197)
0.88% (126)
0.28% (40)
0.26% (37)
0.83% (122)
0.32% (47)
4.09% (540)
1.83% (256)
0.37% (54)
2.99% (240)
1.76% (143)
0.66% (55)
0.59% (49)
1.96% (167)
0.82% (69)
7.22% (517)
3.27% (260)
1.45% (119)
1.69 (1.38, 2.05)
1.50 (1.27, 1.78)
2.30 (1.52, 3.46)
2.20 (1.43, 3.38)
1.77 (1.38, 2.26)
1.86 (1.25, 2.75)
1.47 (1.29, 1.67)
1.47 (1.22, 1.76)
3.53 (2.55, 4.88)
Non-CKD
Rate/Year (# Events)
CKD
Rate/Year (# Events)
Hazard Ratio
(95% CI) CKD to non-CKD hazard ratio
0.5 1 2 4
CKD better Non-CKD better
 Fig. 2. Rates of primary and secondary outcomes according to CKD status at baseline among participants in the 
BP arm of the ACCORD study. 
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Primary outcome
Secondary outcomes
   Non-fatal MI
   Any stroke
   Non-fatal stroke
   Death any cause
   CVD death
   PO/Rev/non-fatal CHF
   Major coronary
   Any CHF
1.30%
0.82%
0.17%
0.17%
0.97%
0.35%
3.90%
1.81%
0.35%
1.48%
0.94%
0.38%
0.34%
0.70%
0.30%
4.27%
1.85%
0.39%
0.88 (0.67, 1.17)
0.87 (0.60, 1.23)
0.45 (0.22, 0.88)
0.50 (0.25, 0.99)
1.41 (0.98, 2.02)
1.22 (0.68, 2.17)
0.90 (0.76, 1.08)
0.98 (0.76, 1.26)
0.87 (0.50, 1.49)
Intensive BP
Rate/Year (n = 1,469)
Standard BP
Rate/Year (n = 1,483)
Hazard Ratio
(95% CI) Intensive to standard hazard ratio
0.50.25 1 2 4
Intensive better Standard better
Primary outcome
Secondary outcomes
   Non-fatal MI
   Any stroke
   Non-fatal stroke
   Death any cause
   CVD death
   PO/Rev/non-fatal CHF
   Major coronary
   Any CHF
2.79%
1.68%
0.50%
0.46%
1.79%
0.78%
7.24%
3.12%
1.40%
3.19%
1.84%
0.82%
0.72%
2.13%
0.85%
7.19%
3.41%
1.51%
0.86 (0.67, 1.11)
0.89 (0.63, 1.24)
0.62 (0.36, 1.08)
0.64 (0.36, 1.15)
0.86 (0.63, 1.16)
0.93 (0.57, 1.49)
1.01 (0.84, 1.20)
0.90 (0.70, 1.15)
0.92 (0.63, 1.32)
Intensive BP
Rate/Year (n = 867)
Standard BP
Rate/Year (n = 859)
Hazard Ratio
(95% CI) Intensive to standard hazard ratio
0.5 1 2 4
Intensive better Standard better
a
b
 Fig. 3. Rates for the primary and secondary outcomes by treatment group (intensive vs. standard) in participants 
without CKD ( a ) and with CKD ( b ) at baseline. 
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 The number of serious adverse events was significant-
ly higher in CKD compared with non-CKD participants 
(87 vs. 57, respectively) and in intensively treated partici-
pants (93 vs. 51 for intensive vs. standard therapy, respec-
tively). The organ-specific serious adverse events that oc-
curred during the study according to CKD status at base-
line and BP arm are depicted in  table 3 .
 Discussion 
 Results of these subgroup analyses of the ACCORD 
data indicate 2 major findings. First, diabetic participants 
with hypertension and mild/moderate CKD have signifi-
cantly more CV events as compared to similar partici-
pants with no CKD. Second, intensive BP control in par-
ticipants with no CKD results in substantial and signifi-
cant reduction of cerebrovascular events, while the same 
level of BP control in persons with baseline CKD shows a 
nonsignificant similar trend for reduction of these events. 
These findings are important and may have clinical im-
plications.
 First, the increased risk for cardiovascular events in 
participants with CKD was true for the primary end 
point, fatal and non-fatal MI, cardiovascular and all-
cause mortality, any and non-fatal stroke and heart fail-
ure. This finding is in line with prior data indicating in-
creased cardiovascular risk in participants with CKD and 
other comorbidities  [1, 12–14] . The risk in general and 
mixed populations is proportional to severity of CKD and 
increases more than 18-fold in participants with ESRD 
 [13, 15] . Data however, for diabetic participants with hy-
pertension and mild CKD are scarce and it is not known 
if indeed they fall in the same risk category as that of oth-
er subgroups with diabetic participants. Data from this 
study strongly suggest that even mild CKD is a strong risk 
factor for cardiovascular events in these participants with 
diabetes and hypertension. Diabetic participants with no 
evidence of CKD do not carry as much risk.
 The second and likely more important finding of our 
study is the effect of intensive BP control on cardiovascu-
lar events in diabetic participants, with and without mild-
to-moderate CKD. In both groups, tight BP control 
showed trends for improvement in cardiovascular events, 
albeit non-statistically significant for most of the out-
comes. The only significant finding was a 55% reduction 
of total and 50% of non-fatal stroke in the non-CKD 
group. In the diabetic-hypertensive CKD population, in-
tensive antihypertensive therapy did show a 30% risk re-
duction in total and non-fatal stroke and a 20% improve-
ment in all-cause mortality but neither reached statistical 
significance.
 The fact, however, that trends for outcome changes 
were in the same direction and numerically similar be-
tween the 2 groups indicates that intensive BP control 
may have similar impacts in participants with and with-
out CKD (test of interaction = NS), but most likely both 
subgroups were underpowered to show significant reduc-
tions in all health outcomes in this ACCORD population. 
Larger studies with longer follow-up will be needed to 
accurately test this hypothesis. We could find very limited 
data on the impact of intensive lowering of BP in partici-
pants with both diabetes and CKD. Future analyses from 
the SPRINT study will shed more light into the question 
whether intensive BP control benefits hypertensive par-
ticipants with baseline high-risk CKD. Although the 
SPRINT study had similar design with ACCORD, dia-
betic participants were not included  [7] .
 The findings of this study showing that intensive re-
duction in BP reduces cerebrovascular events but has lim-
Table 3.  Serious adverse events categories by BP arm and CKD status at baseline
AE_Category int_No CKD_pct std_No CKD_pct int_With CKD_pct std_With CKD_pct
Cardiovascular 26 (1.77) 7 (0.47) 29 (3.34) 14 (1.63)
Digestive 0 (0.0) 2 (0.13) 0 (0.0) 2 (0.23)
Endocrine 1 (0.07) 2 (0.13) 0 (0.0) 1 (0.12)
Excretory 2 (0.14) 2 (0.13) 10 (1.15) 1 (0.12)
Immune/lymphatic 3 (0.20) 2 (0.13) 5 (0.58) 4 (0.47)
Nervous/sensory 3 (0.20) 0 (0.0) 1 (0.12) 2 (0.23)
Respiratory 0 (0.0) 0 (0.0) 2 (0.23) 3 (0.35)
Skeletal 0 (0.0) 1 (0.07) 0 (0.0) 1 (0.12)
Other 5 (0.34) 1 (0.07) 6 (0.69) 6 (0.70)
None 1,429 (97.3) 1,466 (98.9) 814 (93.9) 825 (96.0)
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ited impact on CHD events are consistent with findings 
from other randomized controlled clinical trials of pa-
tients with hypertension and diabetes.
 In the factorial design ADVANCE trial, 11,140 type 
2  diabetics were randomized to fixed combination of 
2 antihypertensive medications or matching placebo. In 
the treated group average, BP was reduced to 135/75 
and in the placebo group to 140/77 mm Hg. Results 
showed a significant 9% overall reduction of major mac-
rovascular and microvascular events  [16] . There was 
also significant relative risk reduction in the total num-
ber of coronary events (14%) and an 18% reduction in 
cardiovascular death. There was a minor nonsignificant 
6% reduction in stroke. In the Systolic Hypertension in 
the Elderly Program, in the subgroup of 583 patients 
with diabetes, BP in the treatment group was 146/70 
mm Hg as compared to 155/74 in the placebo group. All 
major CVD events were reduced by 34%  [17], whereas 
stroke was reduced by 26%. This was a similar relative 
risk reduction as in participants without diabetes, but 
the absolute risk reduction was twice as great for dia-
betic participants. In the Hypertension Optimal Treat-
ment trial, over 18,000 participants were randomized to 
a diastolic BP goal of <90, <85 or <80 mm Hg  [18] . Al-
though the overall study was negative, results in the di-
abetic subgroup (n  = 1,501) were positive. All major 
CVD events were reduced significantly by 51% (p  = 
0.005) in those randomized to diastolic BP goal of 
 ≤ 80 mm Hg compared to a goal of  ≤ 90 mm Hg; 12 vs. 
24 events/1,000 patient-years. In the United Kingdom 
Prospective Diabetes Study, 1,148 participants with 
 hypertension and type 2 diabetes were randomized to 
 either tighter BP control <150/85 mm Hg or less tight 
BP control <180/105 mm Hg  [19] . After 9 years of fol-
low-up, the average BP was reduced to 144/82 vs. 154/87 
mm Hg. Diabetes-related end points were reduced by 
24% (p = 0.005), death related to diabetes by 32% (p = 
0.019), strokes by 44% (p = 0.013), and microvascular 
end points by 37% (p  = 0.009) in the tighter control 
group. All-cause mortality was lower by 18% and MI by 
21% in the more intensively treated group, though not 
statistically significant. In the Systolic Hypertension in 
Europe trial, in 492 participants with diabetes, the mean 
systolic BP was  reduced to 153/77 vs. 162/82 mm Hg 
with significant reductions in CVD mortality, all CVD 
events and stroke  [20] .
 In a recent systematic review/meta-analysis  [21] that 
included 100,354 patients with hypertension and type 
2 DM from 40 studies, it was found that for each 10 mm 
Hg lower systolic BP there was a significant 13% reduc-
tion in all-cause mortality, 11% reduction in cardiovas-
cular events, 12% reduction in coronary heart disease 
events and 27% reduction in the incidence of stroke. Ben-
efit in all cardiovascular events was realized in all sub-
groups with baseline BP >140 mm Hg systolic with treat-
ed pressure reduced to about 135 mm Hg, except for 
stroke. Significant reduction in stroke was found for pa-
tients with baseline BP >140 systolic and <140 mm Hg 
systolic. In fact, the former group achieved an after-treat-
ment systolic BP of 138 mm Hg and a reduction of stroke 
by 24%, and the latter group achieved a systolic BP of 121 
mm Hg and a reduction in stroke by 28%. These data in-
dicate that there is benefit for stroke reduction with 
achieved systolic BP around 120 mm Hg, which is very 
similar with the findings of our study. Unfortunately, 
data in this meta-analysis did not stratify patients by 
CKD status.
 To conclude, in most studies aforementioned, achieved 
BP with intensive treatment was around 135/75 mm Hg. 
Yet treatment showed substantial risk reduction in car-
diovascular events and stroke in a few studies that achieved 
average systolic BP of 121 mm Hg. In our study, the in-
tensive BP arm achieved mean reduction to 119 mm Hg 
and showed significant improvement in stroke condi-
tions. This is also consistent with the results of recent 
SPRINT trial in which intensive therapy led to 30% rela-
tive risk reduction in fatal and non-fatal major cardiovas-
cular outcomes and death from any cause in high risk 
participants without diabetes  [7] .
 In the CKD population, data from randomized con-
trolled trials on intensity of antihypertensive therapy on 
cardiovascular outcomes are scarce. The MDRD and 
AASK trials focused on progression of CKD as primary 
outcomes in non-diabetic CKD participants  [22, 23] . Nei-
ther trial found any significant difference comparing 
mean GFR from baseline to end of treatment between 
standard (140/90 mm Hg) and intensive (125/75 mm Hg) 
BP targets. It should be noted, however, that neither study 
had sufficient statistical power to evaluate the effects of 
more intensive BP intervention on major cardiovascular 
outcomes.
 In our analysis, intensive BP control showed a signifi-
cant risk reduction in stroke in the non-CKD group and 
a similar but nonsignificant trend in the CKD group. Lack 
of statistical significance could be due to a small number 
of participants. Thus, the trends in outcome change were 
concordant in both groups, which is at variance with the 
results of the previous analysis we did on the glycemic 
arm of ACCORD. In that analysis we found that intensive 
glycemic control in patients with mild-to-moderate CKD 
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resulted in marked increase in CV and all-cause mortal-
ity  [23] . The number of serious adverse events noted in 
this study was significantly higher in CKD compared with 
non-CKD participants and in intensively treated patients 
compared to standard treated participants as observed in 
previous trials, in the main ACCORD BP trial  [8] , and in 
a prior analysis of ACCORD according to CKD status 
 [24] .
 In summary, this study demonstrates that in patients 
with hypertension and type 2 DM, even mild CKD is as-
sociated with marked increase in CV events. Intensive BP 
treatments in patients with no CKD results in marked 
reduction of cerebrovascular events and outcomes in pa-
tients with CKD may not be different.
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